Nexus Pharmaceuticals Announces Launch of Potassium Chloride in Water for Injection

Nexus Pharmaceuticals announced the launch of Potassium Chloride in Water for Injection in 10mEq/100mL, 10mEq/50mL, and 20mEq/50mL Single-Dose IV bags.

“Nexus is proud to introduce Potassium Chloride IV Bags to our suite of products,” said Usman Ahmed, Chief Operating Officer of Nexus Pharmaceuticals. “As a critical product for patients, Potassium Chloride is consistently on shortage. We are proud to be a part of the solution to the drug shortage problem by removing obstacles for patient care.”

Nexus Pharmaceuticals’ Potassium Chloride in Water for Injection will be available in environmentally friendly cartons of 24 IV bags.

About Potassium Chloride in Water for Injection

Potassium Chloride in Water for Injection is a sterile, nonpyrogenic, highly concentrated, ready-to-use solution of Potassium Chloride, USP in Water for Injection, USP for electrolyte replenishment in a single-dose container for intravenous administration. Potassium Chloride Injection is indicated in the treatment of potassium deficiency states when oral replacement is not feasible.

For prescribing information, please see the following link.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.